retatrutide type 1 diabetes Blood Sugar Results: 2.02% A1C Drop in Trials Medscape | The investigational triple

The diabetes rate has also remained flat for the past few years, according to Gallups data

One notable difference is that tirzepatide is a dual-agonist (GLP-1 and GIP) while retatrutide is a triple-agonist (GLP-1, GIP, and glucagon)

Women following the retatrutide dose schedule may benefit from planning dose escalations to avoid the luteal phase of their menstrual cycle, when GI sensitivity tends to be highest

They named it a triple agonist because it targets GLP-1, GIP, and glucagon receptors

But it does mean that consistent delivery is arguably more important, because inconsistent absorption could affect the balance of receptor activation

Testing procedures were identical to tirzepatide with the three doses of 0.03 mg/kg, 0.1 mg/kg, and 0.3 mg/kg